Middle East And Africa Drug Delivery Devices Market
Taille du marché en milliards USD
TCAC : %
Période de prévision |
2024 –2031 |
Taille du marché (année de référence) |
USD 26.41 Billion |
Taille du marché (année de prévision) |
USD 48.96 Billion |
TCAC |
|
Principaux acteurs du marché |
>Marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique, par type de produit ( administration de médicaments par voie orale administration de médicaments par voie injectable, administration de médicaments topiques, administration de médicaments ophtalmiques, administration de médicaments par voie nasaleadministration de médicaments par voie pulmonaire , administration de médicaments par voie transmuqueuse et administration de médicaments implantables ), utilisateur final (hôpitaux, soins de santé à domicile, cliniques, soins de santé communautaires et autres), canal de distribution (appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne) - Tendances et prévisions de l'industrie jusqu'en 2031.
Analyse et taille du marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique
Le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique connaît une croissance significative, tirée par la prévalence croissante des maladies chroniques et non chroniques, la croissance du développement de dispositifs de médicaments biologiques et la sensibilisation croissante au diagnostic et au traitement. Le marché est caractérisé par la présence d'un grand nombre d'acteurs proposant une large gamme de dispositifs de diagnostic adaptés aux divers besoins des prestataires de soins de santé de la région.
Data Bridge Market Research analyse que le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique connaît une croissance de 8,3 % au cours de la période de prévision de 2024 à 2031 et devrait atteindre 48,96 milliards USD d'ici 2031 contre 26,41 milliards USD en 2023.
Rapport métrique |
Détails |
Période de prévision |
2024 à 2031 |
Année de base |
2023 |
Année historique |
2022 (Personnalisable 2016-2021) |
Unités quantitatives |
Chiffre d'affaires en milliards USD |
Segments couverts |
Type de produit (administration orale de médicaments, administration injectable de médicaments, administration topique de médicaments, administration ophtalmique de médicaments, administration nasale de médicaments, administration pulmonaire de médicaments, administration transmuqueuse de médicaments et administration implantable de médicaments), utilisateur final (hôpitaux, soins de santé à domicile , cliniques, soins de santé communautaires et autres), canal de distribution (appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne) |
Pays couverts |
Afrique du Sud, Égypte, Arabie saoudite, Émirats arabes unis, Israël et reste du Moyen-Orient et de l'Afrique |
Acteurs du marché couverts |
Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Merck & Co., Inc., Sanofi, West Pharmaceutical Services Inc. entre autres |
Définition du marché
Les dispositifs d'administration de médicaments sont des dispositifs médicaux conçus pour administrer des médicaments à l'organisme de manière contrôlée et ciblée, améliorant ainsi leur efficacité, leur sécurité et l'observance du traitement par le patient. Ces dispositifs peuvent être externes, tels que les inhalateurs, les injecteurs et les pompes, ou internes, tels que les dispositifs implantables, et sont utilisés pour administrer une large gamme de médicaments, notamment des petites molécules, des produits biologiques et des vaccins. Ils peuvent modifier la vitesse de libération, la biodisponibilité et l'absorption des médicaments, ainsi que fournir une surveillance et un retour d'information en temps réel aux patients et aux prestataires de soins de santé. Les dispositifs d'administration de médicaments jouent un rôle crucial dans l'optimisation des résultats du traitement et l'amélioration de la qualité de vie des patients atteints de diverses maladies et affections, notamment les maladies chroniques, les maladies infectieuses et le cancer.
Dynamique du marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique
Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
- Augmentation de la prévalence des maladies chroniques et non chroniques
La prévalence de maladies et d'affections telles que les maladies cardiovasculaires (MCV), l'asthme, le cancer, les troubles neurologiques, les accidents vasculaires cérébraux, le diabète et les maladies respiratoires a considérablement augmenté au fil du temps. Vous trouverez ci-dessous quelques-unes des statistiques importantes liées à certaines maladies chroniques. La prévalence croissante des maladies chroniques et non chroniques influence considérablement la croissance du marché des dispositifs d'administration de médicaments. Les maladies chroniques telles que le diabète, les maladies cardiovasculaires et les troubles respiratoires sont de plus en plus répandues, ce qui nécessite des plans de traitement à long terme qui nécessitent des méthodes de distribution de médicaments efficaces et fiables.
- Croissance dans le développement de dispositifs médicaux biologiques
Les produits biologiques sont considérés comme l'un des segments du marché pharmaceutique connaissant la croissance la plus rapide. Le développement et la fabrication de produits biologiques, qu'il s'agisse de médicaments de marque ou génériques, deviennent de plus en plus compétitifs en raison de la présence de nouveaux acteurs. Les produits biologiques sont généralement administrés par injection dans les bras, les jambes ou l'abdomen. Citons par exemple Cimzia, Cosentyx, Enbrel et Humira, entre autres.
Opportunité
- Acceptation croissante des dispositifs d'auto-administration de médicaments
L'auto-administration de médicaments par les patients devrait offrir des opportunités de croissance importantes aux acteurs du secteur de l'administration de médicaments qui se concentrent sur le développement de dispositifs innovants et nouveaux. Les principaux facteurs contribuant à cette situation sont l'augmentation de la population âgée, car cette population constitue une base de consommateurs importante pour les dispositifs d'administration de médicaments à domicile. Les sociétés pharmaceutiques se concentrent sur le développement de thérapies conviviales pour les patients et de produits combinés médicament-dispositif auto-administrés. Avec l'acceptation croissante de l'auto-administration, le besoin de produits médicamenteux spécifiques à l'application, par injection, inhalation, topique et transdermique, augmente également.
Retenue/Défi
- Effets secondaires des systèmes d'administration de médicaments
Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.
Recent Developments
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
- In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue
Middle East and Africa Drug Delivery Devices Market Scope
The Middle East and Africa drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ophthalmic Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Transmucosal Drug Delivery
- Implantable Drug Delivery
On the basis of product type, the Middle East and Africa drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.
End User
- Hospitals
- Home Healthcare
- Clinics
- Community Healthcare
- Others
On the basis of end user, the Middle East and Africa drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.
Distribution Channel
- Direct Tenders
- Hospital Pharmacies
- Pharmacy Stores
- Online Pharmacy
Sur la base du canal de distribution, le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique est segmenté en appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne.
Analyse/perspectives régionales du marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique
Le marché des dispositifs d’administration de médicaments au Moyen-Orient et en Afrique est analysé, et des informations et tendances sur la taille du marché sont fournies en fonction du type de produit, de l’utilisateur final et du canal de distribution, comme référencé ci-dessus.
Les pays couverts dans ce rapport de marché sont l’Afrique du Sud, l’Arabie saoudite, les Émirats arabes unis, l’Égypte, Israël et le reste du Moyen-Orient et de l’Afrique.
L’Afrique du Sud devrait dominer le marché du Moyen-Orient et de l’Afrique en raison de son secteur de la santé en pleine expansion, de ses investissements substantiels dans l’innovation en matière de technologie médicale et d’une population nombreuse et de plus en plus aisée qui stimule la demande de solutions de santé avancées.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique
Le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique est segmenté en trois segments notables en fonction du type de produit, de l'utilisateur final et du canal de distribution.
Le paysage concurrentiel du marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique.
Certains des principaux acteurs opérant sur le marché des dispositifs d'administration de médicaments au Moyen-Orient et en Afrique sont Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Merck & Co., Inc., Sanofi, West Pharmaceutical Services Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
6.2.2 HIGH COSTS OF INJECTABLE DRUGS
6.2.3 STRINGENT REGULATORY SCENARIO
6.3 OPPORTUNITIES
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY
7 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 ORAL DRUG DELIVERY
7.2.1 SOLID ORAL DRUGS
7.2.1.1 TABLETS
7.2.1.2 CAPSULES
7.2.1.3 PILLS
7.2.1.4 POWDERS
7.2.2 LIQUID ORAL DRUGS
7.2.2.1 SYRUPS
7.2.2.2 SOLUTIONS
7.2.3 SEMI SOLID ORAL DRUGS
7.2.3.1 GELS
7.2.3.2 EMULSIONS
7.2.3.3 ELIXIRS
7.3 INJECTABLE DRUG DELIVERY
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS
7.3.1.3 LONG ACTING INJECTION FORMULATIONS
7.3.2 INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1.1 BY MATERIAL
7.3.2.1.1.1 GLASS
7.3.2.1.1.2 PLASTIC
7.3.2.1.2 BY PRODUCT TYPE
7.3.2.1.2.1 FILLABLE
7.3.2.1.2.2 PRE-FILLED
7.3.2.1.3 BY USABILITY
7.3.2.1.3.1 REUSABLE SYRINGES
7.3.2.1.3.2 DISPOSABLE SYRINGES
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES
7.3.2.2.1 NEEDLE FREE INJECTORS
7.3.2.2.2 WEARABLE INJECTORS
7.3.2.2.3 PEN INJECTOR
7.3.2.2.4 AUTO INJECTORS
7.3.2.2.5 OTHERS
7.4 TOPICAL DRUG DELIVERY
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.1.1 OINTMENTS
7.4.1.1.2 CREAMS
7.4.1.1.3 LOTIONS
7.4.1.1.4 GELS
7.4.1.1.5 PASTES
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.2.1 SUSPENSIONS
7.4.1.2.2 SOLUTIONS
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.3.1 POWDER
7.4.1.3.2 SUPPOSITORS
7.5 OPHTHALMIC DRUG DELIVERY
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1.1 SOLUTIONS
7.5.1.1.2 SUSPENSIONS
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.2.1 GELS
7.5.1.2.2 OINTMENTS
7.5.2 OCCULAR DRUG DELIVERY DEVICES
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DROPS
7.6.2 NASAL SPRAYS
7.6.3 NASAL POWDERS
7.6.4 NASAL GELS
7.7 PULMONARY DRUG DELIVERY
7.7.1 METERED DOSE INHALERS (MDI)
7.7.2 DRY POWDER INHALERS (DPI)
7.7.3 NEBULIZERS
7.7.3.1 JET NEBULIZERS
7.7.3.2 ULTRASONIC NEBULIZERS
7.7.3.3 SOFT MIST NEBULIZERS
7.8 TRANSMUCOSAL DRUG DELIVERY
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
7.8.1.1 BUCCAL DRUG DELIVERY
7.8.1.2 SUBLINGUAL DRUG DELIVERY
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
7.9 IMPLANTABLE DRUG DELIVERY
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
8 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 HOME HEALTHCARE
8.4 CLINICS
8.5 COMMUNITY HEALTHCARE
8.6 OTHERS
9 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 HOSPITAL PHARMACIES
9.4 PHARMACY STORES
9.5 ONLINE PHARMACY
10 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
10.1.1 SOUTH AFRICA
10.1.2 SAUDI ARABIA
10.1.3 U.A.E.
10.1.4 EGYPT
10.1.5 ISRAEL
10.1.6 REST OF MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NOVARTIS AG
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 F. HOFFMANN-LA ROCHE LTD
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BAYER AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.5 PFIZER INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENT
13.6 3M
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 ABBVIE INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 BD
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.1 ELCAM MEDICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ENABLE INJECTIONS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 GERRESHEIMER AG
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
13.13 GSK PLC.
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENTS
13.14 INSULET CORPORATION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 MEDMIX
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENTS
13.16 MERCK & CO., INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 ORASURE TECHNOLOGIES INC.
13.17.1 COMPANY SNAPSHOT
13.17.2 REVENUE ANALYSIS
13.17.3 PRODUCT PORTFOLIO
13.17.4 RECENT DEVELOPMENT
13.18 SANOFI
13.18.1 COMPANY SNAPSHOT
13.18.2 REVENUE ANALYSIS
13.18.3 PRODUCT PORTFOLIO
13.18.4 RECENT DEVELOPMENTS
13.19 SMC LTD.
13.19.1 COMPANY SNAPSHOT
13.19.2 REVENUE ANALYSIS
13.19.3 PRODUCT PORTFOLIO
13.19.4 RECENT DEVELOPMENTS
13.2 VIVO SMART MEDICAL DEVICES LTD.
13.20.1 COMPANY SNAPSHOT
13.20.2 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 WEST PHARMACEUTICAL SERVICES, INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Liste des tableaux
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022
TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 82 SOUTH AFRICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 83 SOUTH AFRICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 84 SOUTH AFRICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 85 SOUTH AFRICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 86 SOUTH AFRICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 87 SOUTH AFRICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 88 SOUTH AFRICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 89 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 90 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 SOUTH AFRICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 92 SOUTH AFRICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 93 SOUTH AFRICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 SOUTH AFRICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 95 SOUTH AFRICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 SOUTH AFRICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 SOUTH AFRICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 SOUTH AFRICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 99 SOUTH AFRICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 100 SOUTH AFRICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 SOUTH AFRICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 SOUTH AFRICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH AFRICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH AFRICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH AFRICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH AFRICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 107 SOUTH AFRICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 108 SOUTH AFRICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 110 SOUTH AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 111 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 112 SAUDI ARABIA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 113 SAUDI ARABIA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 SAUDI ARABIA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 SAUDI ARABIA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 SAUDI ARABIA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 SAUDI ARABIA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 SAUDI ARABIA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 119 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 120 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 121 SAUDI ARABIA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 122 SAUDI ARABIA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 123 SAUDI ARABIA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 124 SAUDI ARABIA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 125 SAUDI ARABIA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 SAUDI ARABIA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 SAUDI ARABIA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SAUDI ARABIA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 129 SAUDI ARABIA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 130 SAUDI ARABIA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SAUDI ARABIA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 SAUDI ARABIA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 133 SAUDI ARABIA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 134 SAUDI ARABIA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 SAUDI ARABIA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 SAUDI ARABIA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 SAUDI ARABIA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 SAUDI ARABIA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 140 SAUDI ARABIA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 141 U.A.E. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 142 U.A.E. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 143 U.A.E. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 144 U.A.E. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 145 U.A.E. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 146 U.A.E. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 147 U.A.E. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 148 U.A.E. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 149 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 150 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 151 U.A.E. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 152 U.A.E. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 153 U.A.E. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 154 U.A.E. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 155 U.A.E. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 U.A.E. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 U.A.E. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 U.A.E. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 U.A.E. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 160 U.A.E. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 U.A.E. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 U.A.E. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 163 U.A.E. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 164 U.A.E. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 165 U.A.E. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 166 U.A.E. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 167 U.A.E. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 168 U.A.E. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 169 U.A.E. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 U.A.E. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 EGYPT DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 172 EGYPT ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 173 EGYPT SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 174 EGYPT LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 175 EGYPT SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 176 EGYPT INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 177 EGYPT INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 178 EGYPT INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 179 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 180 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 181 EGYPT CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 182 EGYPT SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 183 EGYPT TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 184 EGYPT TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 185 EGYPT SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 EGYPT LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 EGYPT LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 EGYPT OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 189 EGYPT OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 190 EGYPT LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 EGYPT SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 EGYPT NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 193 EGYPT PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 194 EGYPT NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 195 EGYPT TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 196 EGYPT ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 197 EGYPT OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 198 EGYPT IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 199 EGYPT DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 200 EGYPT DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 201 ISRAEL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 202 ISRAEL ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 203 ISRAEL SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 204 ISRAEL LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 205 ISRAEL SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 206 ISRAEL INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 207 ISRAEL INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 208 ISRAEL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 209 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 210 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 211 ISRAEL CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 212 ISRAEL SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 213 ISRAEL TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 214 ISRAEL TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 215 ISRAEL SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 ISRAEL LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 ISRAEL SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 ISRAEL OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 219 ISRAEL OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 220 ISRAEL LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 ISRAEL SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 ISRAEL NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 223 ISRAEL PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 224 ISRAEL NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 225 ISRAEL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 226 ISRAEL ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 227 ISRAEL OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 228 ISRAEL IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 229 ISRAEL DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 230 ISRAEL DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 EIGHT SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031
FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET
FIGURE 17 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY END USER, 2023
FIGURE 22 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)
FIGURE 24 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: SNAPSHOT (2023)
FIGURE 30 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.